P53 phosphorylation as prognostic or diagnostic marker for treating senescent cells in mammals

By detecting the specific binding of anti-aging candidate molecules to phosphorylated p53 TAD, and identifying and using FOXO4 reverse turn peptides and other compounds, the problem of identifying and treating cellular aging-related diseases in the prior art is solved, and effective induction of senescent cells is achieved. Apoptosis and cancer prevention effects.

CN118922715APending Publication Date: 2024-11-08CLEARA BIOTECH BV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029724.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-24
Filing Date
2023-03-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to effectively identify and treat degenerative diseases and cancers caused by cellular aging, especially in the phosphorylation of the transcriptional activation domain of mammalian protein p53, and there is a lack of effective anti-aging compound detection methods.

Method used

Improved anti-aging was identified by detecting the specific binding of anti-aging candidate molecules to the transcriptional activation domain (TAD) of mammalian p53 protein in the presence of phosphorylated amino acids, and the binding was compared with the binding in the non-phosphorylated state. Compounds and FOXO4 reverse flip peptide and its derivatives specifically bind to the TAD of p53 to monitor the effectiveness of anti-aging treatment.

Benefits of technology

The selective induction of apoptosis of senescent cells has been achieved, and the effectiveness and preventability of anti-aging treatments have been improved, especially in mutant p53-driven cancers, which significantly reduces the burden of cancer metastasis, providing a new strategy for aging-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005055731770000011
    Figure HDA0005055731770000011
  • Figure HDA0005055731770000021
    Figure HDA0005055731770000021
  • Figure HDA0005055731770000031
    Figure HDA0005055731770000031
Patent Text Reader

Abstract

The present invention relates to a method, in particular an in vitro method, for identifying improved anti-aging compounds based on the detection of the binding of the compounds in the presence of at least one phosphorylated amino acid in the transcriptional activation domain (TAD) of the mammalian protein p53. The invention also relates to a method, in particular an in vitro method, for monitoring an anti-aging treatment or prevention in a mammalian subject in need thereof, it is based on detecting the amount of amino acid phosphorylation in the mammalian p53 protein TAD and / or C-terminal region in a biological sample obtained from the subject and / or detecting the amount of promyelocytic leukemia protein (PML) body and / or co-localization with phosphorylated p53 in a biological sample obtained from the subject. Furthermore, the invention relates to a kit for carrying out the above method and to various uses thereof. Finally, improved anti-aging compounds or pharmaceutical compositions are provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for identifying improved anti-aging compounds based on the detection of the binding of compounds in the presence of at least one phosphorylated amino acid in the transcriptional activation domain (TAD) of mammalian protein p53, in particular an in vitro method. The present invention also relates to a method for monitoring anti-aging treatment or prevention in a mammalian subject in need, in particular an in vitro method, which is based on detecting the amount of amino acid phosphorylation in the TAD and / or C-terminal region of the mammalian p53 protein in a biological sample obtained from the subject and / or detecting the amount of promyelocytic leukemia protein (PML) bodies in a biological sample obtained from the subject and / or co-localization with phosphorylated p53. In addition, the present invention relates to a kit for implementing the above method and its various uses. Finally, an improved anti-aging compound or pharmaceutical composition is provided. Background Art

[0002] Apoptosis (programmed cell death) provides the killing of damaged cells. Dying cells undergoing the final stages of apoptosis present phagocytic molecules that allow these cells to be engulfed by cells with appropriate receptors, such as bacteriophages.

[0003] It has been shown that senescent cells accumulate with age at sites of age-related pathologies. Furthermore, senescent cells can acquire mutations that allow them to reenter a proliferative state. Thus, benign senescent lesions retain the potential to become malignant. Indeed, senescence has been linked to many (age-related) pathologies, and conversely, genetic elimination of senescent cells can delay the hallmarks of aging.

[0004] Cellular senescence is a stress response that in many cases induces permanent cell cycle arrest and causes dramatic phenotypic changes such as the production of a bioactive secretome, also known as the senescence-associated secretory phenotype (SASP). Acute senescence induction can fight cancer and limit fibrosis, but persistent senescent cells drive age-related diseases. Therefore, targeting senescent cells to delay senescence and limit dysfunction, also known as "senotherapy," is gaining momentum. Drugs that selectively kill senescent cells, also known as "senescent cell scavengers," are a major focus, and SASP-centric approaches are emerging as another option for targeting age-related diseases.

[0005] Recently, it has been shown that genetically removing senescent cells can significantly improve health and reduce aging parameters in a mouse model of accelerated aging. These mice show reduced signs of aging, as measured by kyphosis (excessive bone bending), muscle strength, fat accumulation, and cataracts. This provides further evidence that cellular senescence and SASP are causally related to age-related phenotypes and cancer (Baker et al., 2011. Nature 479 (7372): 232-6). This proof-of-concept evidence was obtained in a genetic manner with poor therapeutic application.

[0006] Studies have consistently revealed that FOXO (forkhead box O) transcription factors are important determinants of aging and longevity. FOXO proteins represent a subfamily of transcription factors that are conserved from C. elegans to mammals and serve as key longevity regulators downstream of insulin and insulin-like growth factor signaling pathways. Invertebrate genomes have one FOXO gene, while mammals have four FOXO genes: FOXO1, FOXO3, FOXO4, and FOXO6. In mammals, this subfamily is involved in a wide range of key cellular processes for regulating stress tolerance, metabolism, cell cycle arrest, and apoptosis. Their roles in determining longevity are complex and yet to be fully elucidated.

[0007] Bourgeois and Madl (Regulation of cellular senescence via the FOXO4-p53 axis. FEBS Lett. 2018 Jun; 592(12): 2083-2097) disclosed that in the past decade, both FOXO and p53 have been identified as key factors in aging, and their dysregulation has been associated with a variety of diseases including cancer. However, many of the underlying molecular mechanisms are said to remain unknown, including the regulation of aging by FOXO and p53. FOXO and p53 appear to share some activities, including their central role in regulating cellular senescence. They focus on the latest advances in the association between FOXO and p53, with a particular focus on the FOXO4-p53 axis and the role of FOXO4 / p53 in cellular senescence. Potential strategies for targeting the FOXO4-p53 interaction to regulate cellular senescence as a drug target for treating aging-related diseases and pathologies are discussed.

[0008] Miller Jenkins et al. (in p53 N-terminal phosphorylation: a defining layer of complex regulation, Carcinogenesis, Volume 33, Issue 8, August 2012, Pages 1441–1449, https: / / doi.org / 10.1093 / carcin / bgs145) revealed that the p53 tumor suppressor is a key component of cellular responses to stress. Because it can inhibit cell growth, p53 is mutated or functionally inactivated in most tumors. Numerous protein-protein interactions with transcriptional cofactors are critical for p53-dependent responses. In its activated state, p53 is extensively modified in the N- and C-terminal regions of the protein. These modifications, particularly phosphorylation of serine and threonine residues in the N-terminal transcriptional activation domain, affect the stability and activity of p53 by modulating the affinity of protein-protein interactions. They review recent findings from in vitro and in vivo studies involving p53 N-terminal phosphorylation. These modifications can affect p53 either positively or negatively and add a second layer of complex regulation to the various interactions of the p53 transcriptional activation domain.

[0009] Feng et al. (Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle. 2006 Dec; 5(23): 2812-9. doi: 10.4161 / cc.5.23.3526. Epub 2006 Dec 1. PMID: 17172844) revealed that cell line studies have shown that phosphorylation of Ser46 is associated with the activation of p53 apoptotic activity.

[0010] Baar MP et al. (Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017 Mar 23; 169(1): 132-147. e16. doi: 10.1016 / j.cell.2017.02.031. PMID: 28340339; PMCID: PMC5556182) revealed a FOXO4 peptide that disrupts the interaction between FOXO4 and p53. In senescent cells, it selectively causes p53 nuclear exclusion and cell-intrinsic apoptosis. This peptide exhibits apoptosis-inducing activity in senescent cells, or in cells that show increased FOXO4 expression relative to control cells and express Ser15 phosphorylated p53.

[0011] WO 2019 / 069070 A1 discloses artificial peptides for senescence clearance, which, when intermittently administered, can selectively kill senescent cells in mammals. DNA-damaged melanoma cells in which Foxo4 expression is disrupted cause a significant increase in apoptosis. These findings indicate that the presence of Foxo4 inhibits apoptosis through p53 phosphorylation at S46. In addition, it has been shown that inhibition of kinases that phosphorylate p53 at S46 causes apoptosis of damaged senescent cells even in the absence of Foxo4. Thus, a key role for Foxo4 in inhibiting apoptosis mediated by p53 phosphorylation at S46 is proposed.

[0012] WO 2016 / 118014 relates to a peptide containing the amino acid sequence LTLRKEPASEIAQSILEAYSQNGWANRRSGGKRP (SEQ ID NO: 7), wherein the amino acids in the amino acid sequence are D-amino acid residues, and to methods of using the peptide in treating age-related diseases. The peptide exhibits apoptosis-inducing activity in senescent cells, or cells in which FOXO4 expression is increased relative to control cells and expresses Ser15 phosphorylated p53 (pSer15-p53).

[0013] WO 2013 / 152038 relates to the use of an agent that inhibits Jun kinase and / or FOXO4 to treat cancer and / or remove senescent cells in an individual. In some embodiments, the agent is a small molecule, such as SP600125. In some embodiments, the agent is a small molecule, such as AS601245. In some embodiments, the agent is a disclosed peptide.

[0014] WO 2013 / 152041 relates to an agent that inhibits the function of FOXO4 and its use in treating cancer and / or removing senescent cells in an individual. In some embodiments, the agent that inhibits FOXO4 is a peptide that inhibits the function of FOXO4 in a cell, wherein the peptide comprises the disclosed amino acid sequence that has at least 80% identity with a FOXO4 fragment.

[0015] WO 2018 / 129007 relates to conditionally activated proteins targeting senescent cells and methods for preparing the conditionally activated proteins.

[0016] WO 2021 / 165538 relates to improved compounds for treating diseases or conditions that benefit from the removal of senescent cells, scar cells, and / or cancer cells, such as cancer. WO 2021 / 165538 also relates to methods for treating individuals suffering from, or suspected of suffering from, a disease or condition that benefits from the removal of senescent cells, scarred cells, and / or cancer cells.

[0017] From the foregoing, it is clear that there remains a need in the art for improved assays and methods to identify effective disease treatments that can be treated with compounds that selectively induce apoptosis in senescent cells. Cellular senescence is particularly associated with degenerative (loss of function) diseases and cancer (gain of function), both of which involve the mammalian protein p53. It is therefore an object of the present invention to provide assays and methods for identifying effective disease treatments that can be treated with compounds that selectively induce apoptosis in senescent cells. Summary of the invention

[0018] In its first aspect, the present invention solves the above problems by providing a method for identifying improved anti-aging compounds, comprising the steps of: a) contacting at least one anti-aging candidate molecule with the transcriptional activation domain (TAD) of a mammalian p53 protein, b) detecting specific binding of the candidate molecule to the TAD in the presence of at least one phosphorylated amino acid in the TAD, and c) comparing the specific binding with the binding in the absence of at least one phosphorylated amino acid in the TAD, wherein an enhanced binding in the presence of at least one phosphorylated amino acid in the TAD identifies an improved anti-aging compound. In its most preferred embodiment, the method of the present invention is used to identify improved retro-inverso peptides derived from mammalian FOXO4 proteins, fusion peptides containing the retro-inverso peptides derived from mammalian FOXO4 proteins, and derivatives thereof, preferably peptides selected from CL04183, CL04124 and CL04177 (see below) or their core sequences.

[0019] Preferably, according to the method of the present invention, the phosphorylation of TAD1 is located at Ser15 and / or Ser20 of human p53, and / or the phosphorylation of TAD2 is located at Ser46 and / or Thr55 of human p53, or similar positions in other p53 TADs. Preferably, the phosphorylation of TAD2 is located at Thr55 of human p53, or similar positions in other mammalian p53 TADs. In other preferred embodiments of the method of the present invention, the detection of binding also includes, when feasible, detecting the phosphorylation of Ser392 in the C-terminal region of human p53 or similar positions in other mammalian p53 proteins, and comparing the specific binding with the absence of the phosphorylated amino acid.

[0020] In its second aspect, the present invention solves the above-mentioned problem by providing an anti-aging compound identified according to the method of the present invention, or a pharmaceutical composition comprising the anti-aging compound and a pharmaceutically acceptable carrier.

[0021] In its third aspect, the present invention solves the above-mentioned problem by providing a method for monitoring anti-aging treatment or prevention in a mammalian subject in need thereof, which comprises a) providing anti-aging treatment or prevention to the subject, comprising administering to the subject an anti-aging compound that specifically binds to the p53 protein TAD, or a pharmaceutical composition comprising the anti-aging compound, preferably a compound or pharmaceutical composition according to the present invention, b) detecting the amount of phosphorylation of amino acids in the p53 protein TAD in a biological sample obtained from the subject, and / or detecting the amount of promyelocytic leukemia protein (PML) bodies, and / or detecting the colocalization of promyelocytic leukemia protein (PML) bodies with phosphorylated p53 protein in a biological sample obtained from the subject, and c) comparing the amount and / or colocalization detected in step b) with the amount and / or colocalization in a sample previously obtained from the subject and / or a control sample.

[0022] In its fourth aspect, the present invention provides a method for predicting or prognosing the success, progression and / or sensitivity of anti-aging treatment or prevention in a mammalian subject, comprising implementing a method according to the invention, wherein an increase in phosphorylation and / or co-localization of PML protein and / or phosphorylated p53 with PML indicates the success, progression and / or sensitivity of anti-aging treatment or prevention in a mammalian subject.

[0023] In its fifth aspect, the present invention solves the above-mentioned problem by providing an anti-aging compound that specifically binds to the TAD of the p53 protein, or a pharmaceutical composition comprising the anti-aging compound, preferably a compound or pharmaceutical composition according to the present invention, for use in the prevention or treatment of senescent cells, wherein the senescent cells, when compared to control cells, exhibit an increase in the amount of phosphorylation of Ser46 and / or Thr55 of human p53, or similar positions in other mammalian p53 TAD, and / or an increase in the amount of PML protein.

[0024] Preferred is the use of an anti-aging compound or pharmaceutical composition according to the present invention, wherein the senescent cells, when compared to control cells, also exhibit an increase in the amount of phosphorylation of Ser392 in the C-terminal region of human p53, or a similar position in other mammalian p53 proteins. Also preferred is the use of an anti-aging compound or pharmaceutical composition according to the present invention, wherein the senescent cells are selected from primary tumor cells, metastatic tumor cells, cells of secondary tumors, cells of micrometastasis and / or macrometastasis, fibrotic cells, breast cancer cells (e.g., triple-negative breast cancer cells), lung cancer, ovarian cancer, pancreatic cancer, gastric cancer, and / or liver cancer cells or metastatic cells thereof.

[0025] In its sixth aspect, the present invention solves the above problem by providing a method for preventing or treating senescent cells in a subject, wherein the senescent cells, when compared to control cells, exhibit an increase in the amount of phosphorylation of Ser46 and / or Thr55 of human p53, or similar positions in other mammalian p53 TADs, and / or an increase in the amount of PML protein, the method comprising administering to the subject an effective amount of an anti-aging compound that specifically binds to the p53 protein TAD or a pharmaceutical composition comprising the anti-aging compound, preferably a compound or pharmaceutical composition according to the present invention.

[0026] Preferred is a method according to the invention, wherein the senescent cells, when compared to control cells, also exhibit an increase in the amount of phosphorylation of Ser392 in the C-terminal region of human p53 or a similar position of other mammalian p53 proteins. Further preferred is a method, wherein the senescent cells are selected from primary tumor cells, metastatic tumor cells, cells of secondary tumors, cells of micrometastasis, fibrotic cells, breast cancer cells (e.g. triple negative breast cancer cells), lung cancer, ovarian cancer, pancreatic cancer, gastric cancer, and / or liver cancer cells or metastatic cells thereof.

[0027] The present invention is based on the unexpected discovery of the inventors that phosphorylation of the p53 protein is an important factor in the effective binding of anti-aging molecules to the TAD and / or C-terminal regions of p53. TAD1 and 2 contain four amino acid residues whose charge can change due to phosphorylation. The FOXO4-FH derivative conjugates disclosed herein specifically interact with TAD2, indicating that S46 and T55 are more important for binding and selectivity. The FOXO4-FH derivative conjugates identified according to the present invention, such as CL04183, bind more tightly to the phosphorylated Ser46 / Thr55 than to the non-phosphorylated one (see Fig.16 ). Ser392 was also found to be relevant (see below).

[0028] In the above background, the current invention analyzes the binding efficiency of certain anti-aging compounds, such as the reverse-order flip peptides (wherein the amino acids in the amino acid sequence are D-amino acid residues) obtained from mammals, especially human forkhead box protein O4 (FOXO4), to p53 protein. Preferred examples are compounds comprising the following amino acid sequences: RKKASSKIEAAILDAFSQNWRFFKRPPRRRQRRKKRG (SEQ ID NO: 1; referred to as CL04124); RKKASSKIEAEILDAFSQNWRRKRPPRRRQRRKKRG (SEQ ID NO: 2; referred to as CL04177); and AKIEAAILDAFSQNWRKRRRRQRRKKRG (SEQ ID NO: 3; referred to as CL04183).

[0029] It was also found that, independently of the above, the binding of anti-aging molecules was also strongly affected by phosphorylation of p53 protein at position S392, and it was found that phosphorylation of S392 caused p53 to adopt an "open" configuration, and some of the preferred anti-aging molecules tested, such as the molecule CL04183, were particularly effective against pS392-containing and / or "open"-p53 (see, for example, Fig.14 ).

[0030] Promyelocytic leukemia protein (PML) (also known as MYL, RNF71, PP8675 or TRIM19) is the protein product of the PML gene. The PML protein is a tumor suppressor protein required for the assembly of multiple nuclear structures (called PML-nuclear bodies or PML (protein) bodies, which are formed in the chromatin of the cell nucleus). These nuclear bodies are present in mammalian cell nuclei, with approximately 1-30 per nucleus. PML-(N)B is known to have multiple cellular regulatory functions, including involvement in programmed cell death, genome stability, antiviral effects and control of cell division. It is known that PML mutations or loss, and the subsequent dysregulation of these programs, are associated with a variety of cancers.

[0031] In addition to the above, in the context of the present invention, it was surprisingly found that PML bodies can be used as a "proxy p53 biomarker" for the efficacy of certain preferred anti-aging molecules tested, such as the molecule CL04183. CL04183 was found to be particularly effective against cells with pS392 / "open"-p53 and PML elevation and / or phosphorylated p53 co-localized with PML (see, e.g. Fig.12 ), especially against PML in the liver and lungs 高 This is likely due to the fact that tumor metastasis requires an initiating stem-like state and PML is associated with the “stem-like” state, specifically CD44 and active β-catenin.

[0032] Diana Putavet et al. (Repurposing the FOXO4 senolytic against triple-negative breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022; 82 (4 Suppl): Abstract nr P1-19-02) revealed that triple-negative breast cancer (TNBC) has a particularly poor prognosis, partly due to the lack of relevant molecular targets in these tumors. The most commonly mutated gene in TNBC is the tumor suppressor p53. They found that in TNBC, mutated p53 has a unique configuration that has a new carcinogenic effect by binding to the transcription factor forkhead box O (FOXO) 4 hidden in promyelocytic leukemia (PML)-based aggregates. Because these nuclear structures are specific to senescent cells, we tested FOXO4 peptides that clear senescent cells. In cytotoxicity experiments, we found that this compound targets TNBC more specifically than other breast cancer subtypes. Most importantly, these compounds reduce metastatic burden in the most commonly used mouse model of human breast cancer metastasis. They show that cancers driven by mutant p53 present specific features of senescent cells, making them good candidates for FOXO4-directed anti-senolytic therapy. Creative use of senescent cell scavengers could be translated to other cancer types driven by mutant p53. No mention of phosphorylation of p53 was made.

[0033] In the context of the present invention, the term "TP53" or "p53" will refer to the mammalian protein p53, in particular human TP53, mouse Trp53, rat Tp53, the gene of monkey, sheep, goat, hamster, dog or cat TP53. It also includes all natural variants and functional fragments of p53 that bind to FOXO4 protein or its fragments, in particular the transactivation domain (TAD) or transcriptional activation domain. The amino acid sequence of human p53 can be found in P04637.

[0034] In the context of the present invention, the term "TAD" will refer to one of the two different transactivation domains at the N-terminus of the above-mentioned p53 protein. Raj and Attardi (The Transactivation Domains of the p53 Protein. Cold Spring Harb Perspect Med. 2017; 7(1): a026047. Published 2017 Jan 3. doi: 10.1101 / cshperspect.a026047) disclosed the structure and function of the TAD of p53 (see in particular Figure 1 ). Also disclosed are serines and threonines in the p53 TAD (approximately positions 1-85 / 92) that are phosphorylation targets and affect the interaction of the p53 TAD with binding partners. When including the carboxyl terminus of what is now considered to be the proline-rich binding domain (PRD), human TAD1 is approximately amino acids 1-40 / 42, and TAD2 is approximately amino acids 41 / 43-63 or 92, see Figure 1 .

[0035] Thus, as described above, in its first aspect, the present invention solves the above problems by providing a method, in particular an in vitro method, for identifying improved anti-aging compounds, comprising the steps of: a) contacting at least one anti-aging candidate molecule with the transcriptional activation domain (TAD) of a mammalian p53 protein, b) detecting specific binding of the candidate molecule to the TAD in the presence of at least one phosphorylated amino acid in the TAD, and c) comparing the specific binding with the binding in the absence of the at least one phosphorylated amino acid in the TAD, wherein an enhanced binding in the presence of at least one phosphorylated amino acid in the TAD identifies an improved anti-aging compound. In its most preferred embodiment, the method of the present invention is used to identify improved retro-flip peptides derived from mammalian FOXO4 proteins, fusion peptides containing the retro-flip peptides derived from mammalian FOXO4 proteins, and derivatives thereof, preferably peptides selected from CL04183, CL04124 and CL04177 (see below) or their core sequences.

[0036] Figure 3Results of binding assays are shown, demonstrating that FOXO4 (A) and FOXO4-derived (eg, mimetic) peptides (B) and (C) bind with significantly higher affinity to p53-TAD2 when phosphorylated at either T55 or S46. Figure 4 It was shown that the FOXO4-derived peptide CL04183 can bind to full-length p53 in cells in the wild-type or T55 or S46 phosphorylation mimics, but not when these sites cannot be phosphorylated. Fig.11 It is shown that cancer cells that survive chemotherapy show increased PML bodies and phosphorylated p53. These cells are more sensitive to CL04183 treatment, see Fig.13 .

[0037] Preferred is the method according to the invention, wherein the contact is in vivo or in vitro, in solution, or comprises a mammalian p53 protein TAD or an anti-aging candidate compound bound or coupled to a solid phase carrier. Each form is also described in the art and is known to those skilled in the art.

[0038] Preferably, the method according to the present invention, wherein the phosphorylation of TAD1 is located at Ser15 and / or Ser20 of human p53, and / or the phosphorylation of TAD2 is located at Ser46 and / or Thr55 of human p53, or a similar position of other mammalian p53 TADs. Preferably, the phosphorylation of TAD2 is located at Thr55 of human p53, or a similar position of other mammalian p53 TADs. In another preferred embodiment of the method according to the present invention, the detection of binding also includes, when feasible, detecting the phosphorylation of Ser392 of human p53 or a similar position of other mammalian p53 proteins, and including comparing the specific binding with the absence of the phosphorylated amino acid.

[0039] In the context of the present invention, any suitable mammalian TAD can be used. Preferably, the method according to the present invention, wherein the TAD of the mammalian p53 protein is selected from TAD1 and / or TAD2 of human, mouse, rat, monkey, sheep, goat, hamster, dog, and cat p53 protein, optionally a part of the full-length p53 protein, in particular a recombinant p53 protein, a full-length p53 protein containing phosphorylation of Ser392 of human p53 or a similar position of other mammalian p53 proteins, a recombinant fusion protein comprising the TAD1 and / or TAD2 or a phosphorylated fragment of TAD1 or TAD2, and a mutant thereof. Preferably, the phosphorylation of the TAD1 domain is located at Ser15 and / or Ser20 of human p53, and / or the phosphorylation of the TAD2 is located at Ser46 and / or Thr55 of human p53, or a similar position of other mammalian p53 TADs.

[0040] In the context of the present invention, the anti-aging candidate molecules can be selected from any suitable molecules suitable for binding to mammalian p53, such as organic chemical molecules, molecules selected from organic small molecule libraries (molecular weight less than 500Da), molecules selected from combinatorial libraries, cell extracts (especially plant cell extracts), small molecule drugs, proteins, protein fragments, molecules selected from peptide libraries, antibodies or fragments thereof. Particularly preferred are reverse-flip peptides obtained from mammalian FOXO4 proteins, fusion peptides comprising reverse-flip peptides obtained from mammalian FOXO4 proteins, and derivatives thereof, preferably peptides selected from CL04183, CL04124 and CL04177, as explained above. Other peptides are disclosed in WO 2021 / 165538 (incorporated herein by reference for this purpose). These candidate molecules are used as the basis for screening improved compounds in which certain amino acids are modified (see below).

[0041] If the anti-aging candidate molecule is a peptide, the compound may also contain a sequence that confers cell penetration properties, organelle targeting properties, nuclear localization, mitochondrial localization, blood-brain barrier permeability, cell membrane localization, and / or peptidase cleavage, such as, for example, the TAT sequence of HIV (GRKKRRQRRRPP, SEQ ID NO: 8), or ARKKRRQRRRPPP (SEQ ID NO: 9). If the anti-aging candidate molecule is a peptide, the compound may also contain non-naturally occurring amino acids, preferably having the same or substantially the same desired properties as the natural amino acid at that position of the compound, modified amino acids, such as, for example, linker amino acids, staplers, cysteine ​​bonds, glycosylation sites, ubiquitination and / or pegylation sites.

[0042] In the context of the present invention, any method suitable for detecting compound binding can be used. Each method is known to those skilled in the art and is disclosed in the art. Preferably, the method according to the present invention, wherein the detection of the binding includes detection of phosphorylation, including radiolabeled 32P orthophosphate, phosphorylation-specific antibodies, and / or mass spectrometry.

[0043] Components of the assays disclosed herein can be labeled, for example, with a radioactive or fluorescent marker or an antigenic marker.

[0044] In another aspect of the invention, detection of binding includes competitive binding of a compound, in particular a peptide, such as CL04177, CL04124 or CL04183, to the protein FOXO4 or its TAD binding peptide, i.e., detection of the modified compound in the presence of at least one compound (compared to the absence of the compound), compared to the absence of the compound, and in different phosphorylation states thereof.

[0045] Detection of binding may also include, when feasible, detecting phosphorylation at Ser392 of human p53 or a similar position of other mammalian p53 proteins, and comparing the specific binding to that in the absence of the phosphorylated amino acid. Again, this can be done using a suitable selective antibody.

[0046] Another aspect of the present invention relates to a method for identifying improved compounds that bind to the TAD of p53 or its FOXO4 binding fragment, or bind to p53 and inhibit the interaction between FOXO4 and p53 in cells, comprising the following steps: a) providing at least one anti-aging candidate compound; b) appropriately modifying the compound of a); c) contacting at least one anti-aging candidate molecule of b) with the transcriptional activation domain (TAD) of mammalian p53 protein; d) detecting the specific binding of the candidate molecule to the TAD in the presence of at least one phosphorylated amino acid in the TAD; and e) comparing the specific binding with the binding in the absence of at least one phosphorylated amino acid in the TAD, wherein the enhanced binding in the presence of at least one phosphorylated amino acid in the TAD identifies the improved anti-aging compound.

[0047] Preferably, the method according to the present invention further comprises detecting the activity of the identified compound in inducing apoptosis and / or killing senescent, scar and / or tumor cells, preferably comprising determining elevated caspase-3 / 7 activity, loss of mitochondrial cytochrome C, TUNEL positivity, extracellular annexin V positivity, and / or elevated cell death markers (e.g., cellular propidium iodide inclusion, lactate dehydrogenase release assay, and / or loss of viability, such as loss of calcein-AM integration or MTS viability assay).

[0048] Also preferred is a method according to the invention, wherein the TAD or a FOXO4 binding fragment thereof is recombinantly expressed in the cell.

[0049] The present invention also relates to designed improved inhibitory compounds, since the evolutionary differences between FOXO1 / 3 / 6 and FOXO4 suggest that some amino acids can be changed or modified to create improved inhibitory compounds. All of these modifications present new strategies, any of which, or combinations thereof, ultimately lead to the "rational design" of improved molecules for use in the context of the present invention. The present invention also includes strategies to further improve compounds that have only partially undergone "directed evolution" or "directed mutagenesis."

[0050] In the process of "rational design" of improved compounds used in the context of the present invention, in order to further improve a compound that has only partially been subjected to "directed evolution" or "directed mutagenesis", the compound may be subjected to multiple consecutive rounds of the above methods.

[0051] After providing a compound (e.g., a peptide), for example, after its appropriate chemical synthesis, the compound can be modified. In general, many methods of how to modify the compounds of the invention are known to those skilled in the art and are described in the literature. Modifications of compounds will generally fall into a number of categories, such as a) mutation / change of amino acids to different amino acids, b) chemical modification of amino acids, such as via the addition of additional chemical groups, c) modification of amino acid structure (e.g., L- to D-form) or linkages (e.g., introduction of reverse flipping linkages), d) changes in the length of the compound, and e) attachment of additional groups to the molecule (including marker groups, labels, linkers or carriers, such as chelators).

[0052] As described above, the evolutionary differences between FOXO1 / 3 / 6 and FOXO4 suggest that some amino acids can still be modified to create improved compounds that exhibit the desired binding and - ultimately - inhibitory activity. Analysis of the FOXO4-FH fragment and the p53-TAD2 domain showed that the negative charge in p53 mediates binding to FOXO4, as well as the hydrophobic Tyr. Thus, the amino acids of the peptides according to the invention can be mutated into positively charged amino acids that are beneficial to the strength of the interaction. Examples are lysine (K), arginine (R), and histidine (H). NMR experiments also show that the negatively charged amino acids in p53 are responsible for interacting with FOXO4 around the SQ motif (site). This site can become phosphorylated, and to prevent this from happening, the site is mutated into a small nucleotide, such as alanine (A), glycine (G) or serine (S). Methods for introducing these mutations are known to the skilled person and include introducing changes during the chemical synthesis of the peptide, or genetic methods in which the peptide encoding nucleotide sequence is correspondingly altered, such as nucleotide-based mutations, mutations including PCR, etc. At the same time, random mutagenesis is feasible.

[0053] In addition, amino acids can be changed by chemical modification, for example, by adding additional chemical groups during the synthesis process, or by post-translational or post-synthetic modification. Methods for modifying amino acids are well known in the prior art and are summarized in, for example, Christopher D. Spicer & Benjamin G. Davis. Selective chemical protein modification Nature Communications volume 5, Article no.: 4740 (2014) or Sakamoto S, Hamachi I. Recent Progress in Chemical Modification of Proteins. At the same time, modifications of the amino acid structure (e.g., L- to D-type) or the connection between amino acids (e.g., introducing a reverse order flip connection during the synthesis process) can be performed.

[0054] Finally, additional chemical and / or functional groups may be introduced into the molecule, such as, for example, marker groups, labels, linker amino acids, staplers, cysteine ​​bridges, glycosylation sites, ubiquitination and / or pegylation sites, linkers or carriers, such as chelators.

[0055] In the next step, the modified compound is tested for at least one binding of at least one compound to the TAD of p53 in its different phosphorylation states. As discussed herein, the properties of the compound binding to the TAD and its phosphorylation state are necessary for all uses of the compound, whether they are used for treatment or diagnosis. In the context of the present invention, "improved" binding includes scenarios in which the modified compound binds to the unmodified (i.e., starting) compound to the same extent, although the compound has been modified (e.g., dimerized or by adding markers or other groups). Preferably, it is modified to exhibit a stronger binding to the target, i.e., the TAD of p53, in its phosphorylated state. It is also preferred that, for example, due to the improved stability of the modified compound in vitro or in vivo, a compound that shows a more persistent binding to the target, i.e., the TAD or its binding fragment.

[0056] Assays for detecting binding of a compound to a target (ie, TAD) are well known to the skilled artisan and preferably include mass spectrometry, NMR detection, pull-down detection, and the like.

[0057] As described above, the property of the compound to bind to the TAD and its phosphorylation state is essential for all uses of the compound, whether they are used for treatment or diagnosis. Ideally, the binding is also specific for the intended target, i.e., the TAD, or at least fairly or substantially specific. This will reduce or avoid any unwanted side effects in the medical use of the compound, and reduce or avoid any background or false positive results in diagnostic use.

[0058] In the last step of the method, in a preferred aspect of the invention, an improved compound is identified that binds to the TAD of p53, in particular TAD2 of p53, depending on the phosphorylation state, preferably to the TAD depending on the phosphorylation state and inhibits the interaction of FOXO4 with p53 in the cell, compared to the compound provided at the beginning of the method. This function is considered to be necessary for the therapeutic function of the compounds of the invention by eliminating senescent cells, and the improved diagnostic molecules according to the invention may not mandatorily require these properties / functions.

[0059] Identification of these improved compounds can include testing the potency of these compounds, such as FOXO4-peptides, to better bind phosphorylated TADs and eliminate senescent cells, and optionally identifying the structural requirements that determine this property; and / or testing the selectivity of these compounds, such as FOXO4-derived peptides, to eliminate senescent cells, and again, optionally identifying the structural requirements that determine this property.

[0060] Preferably, the improved compound, such as a peptide or improved peptide according to the present invention, is considered to exhibit apoptosis-inducing activity in senescent cells if it kills, eliminates, removes or reduces the viability of at least 5, 10, 15, 20, 30, 40, 50, 60, 70, or 80% of the cells in the senescent cell culture. Preferably, the peptide according to the present invention exhibits apoptosis-inducing activity selectively in senescent cells (i.e., not in non-senescent cells). The peptide according to the present invention prefers apoptosis in senescent cells by a factor of 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3, 4, 5 or more compared to apoptosis in non-senescent cells.

[0061] The peptide compounds according to the invention are preferably isolated. The peptide compounds according to the invention are preferably produced using a suitable peptide synthesis.

[0062] Another aspect of the present invention relates to an improved anti-aging compound identified by the method according to the present invention, or a pharmaceutical composition comprising the anti-aging compound and a pharmaceutically acceptable carrier.

[0063] The pharmaceutical composition used may optionally contain a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers or excipients include diluents (fillers, expanders, such as lactose, microcrystalline cellulose), disintegrants (e.g., sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose), binders (e.g., PVP, HPMC), lubricants (e.g., magnesium stearate), glidants (e.g., colloidal SiO2), solvents / cosolvents (e.g., aqueous carriers, propylene glycol, glycerol), buffers (e.g., citrate, gluconate, lactate), preservatives (e.g., sodium benzoate, parabens (Me, Pr and Bu) esters, BKC), antioxidants (e.g., BHT, BHA, ascorbic acid), wetting agents (e.g., polysorbates, sorbitan esters), thickeners (e.g., methylcellulose or hydroxyethylcellulose), sweeteners (e.g., sorbitol, saccharin, aspartame, acesulfame potassium), flavoring agents (e.g., mint, lemon oil, butterscotch), humectants (e.g., propylene glycol, glycerol, sorbitol). Other suitable pharmaceutically acceptable excipients are described in Remington's Pharmaceutical Sciences, 15 th Ed., Mack Publishing Co., New Jersey (1991) and Bauer et al., Pharmazeutische Technologic, 5 th Ed., Govi-Verlag Frankfurt (1997). Those skilled in the art are aware of suitable peptide formulations and will be able to readily select suitable pharmaceutically acceptable carriers or excipients based on, for example, the formulation of the pharmaceutical composition and the route of administration.

[0064] The pharmaceutical composition can be administered orally, for example in the form of pills, tablets, coated tablets, sugar-coated tablets, hard and soft gelatin capsules, liquids, syrups, emulsions or suspensions or as aerosol mixtures. However, it can also be administered rectally, for example in the form of suppositories, or parenterally, for example as injections or infusions, or transdermally, for example in the form of ointments, creams or tinctures.

[0065] In addition to the compounds of the present invention described above, the pharmaceutical composition may contain other conventional, usually inert carrier materials or excipients. Thus, the pharmaceutical preparation may also contain additives, such as fillers, extenders, disintegrants, binders, glidants, sweeteners, stabilizers, emulsifiers, preservatives, sweeteners, colorants, flavoring or aromatic agents, buffer substances, and additional solvents or solubilizers or agents for achieving storage effects, and salts, coating agents or antioxidants for changing osmotic pressure. They may also contain salts of two or more compounds of the present invention described above, as well as other therapeutically effective substances described herein.

[0066] Another aspect of the present invention relates to a method for monitoring anti-aging treatment or prevention in a mammalian subject in need, such as a diagnostic method, which comprises a) providing anti-aging treatment or prevention to the subject, comprising administering to the subject an anti-aging compound that specifically binds to the p53 protein TAD, or a pharmaceutical composition comprising the anti-aging compound, preferably a compound or pharmaceutical composition according to the present invention as described herein, b) detecting the amount of phosphorylation of amino acids in the p53 protein TAD in a biological sample obtained from the subject, and / or detecting the amount of promyelocytic leukemia protein (PML) bodies, and / or detecting the co-localization of promyelocytic leukemia protein (PML) bodies with phosphorylated p53 protein in a biological sample obtained from the subject, and c) comparing the amount and / or co-localization detected in step b) with the amount and / or co-localization in a sample previously obtained from the subject and / or a control sample. Preferably, an increase in the amount of phosphorylated and / or PML bodies and / or the co-localization of phosphorylated p53 and PML indicates the success, progress and / or sensitivity of anti-aging treatment or prevention in a mammalian subject. The method may also include adjusting treatment or prevention in the mammalian patient based on the monitoring.The attending physician will be able to conveniently make and apply each treatment decision, taking into account other patient parameters if necessary.

[0067] Similarly, another aspect of the invention relates to a method of predicting or prognosing the success, progress and / or sensitivity of an anti-aging treatment or prevention in a mammalian subject, such as a diagnostic method, comprising implementing the method according to the invention as described herein, wherein an increase in phosphorylation and / or PML bodies and / or co-localization of phosphorylated p53 with PML indicates the success, progress and / or sensitivity of an anti-aging treatment or prevention in a mammalian subject. As described herein, the current inventors surprisingly discovered that phosphorylation of the TAD of p53, and / or the amount of PML bodies and / or co-localization of phosphorylated p53 with PML, is directly correlated with the success, progress and / or sensitivity of an anti-aging treatment or prevention.

[0068] Preferred is the method according to the invention, wherein the mammalian subject is a human, mouse, rat, monkey, sheep, goat, hamster, dog, or cat.

[0069] Preferred is a method according to the present invention, wherein the anti-aging treatment or prevention in a mammalian subject comprises administering an effective amount of the compound identified herein, the pharmaceutical composition, a retro-flip peptide obtained from a mammalian FOXO4 protein, a fusion protein comprising a retro-flip peptide obtained from a mammalian FOXO4 protein, and derivatives thereof, preferably a peptide selected from CL04183, CL04124 and CL04177 and their TAD2 binding derivatives or fragments.

[0070] As described herein, the compound is administered to the subject at an effective dose. The dose may vary within a wide range and be suitable for individual circumstances in each individual case. For the above-mentioned uses, the appropriate dose will vary based on the mode of administration, the specific condition to be treated, and the desired effect. However, generally speaking, the dose rate as described above achieves satisfactory results, such as about 1-100 mg / kg animal body weight, particularly 1-50 mg / kg. For large mammals such as humans, the appropriate dose rate is about 10 mg-3 g / day, usually conveniently used in a single dose, or in a divided dose, such as 2-4 times a day, or in a sustained release form. Generally speaking, in the case of oral administration, a daily dose of about 10 mg-100 mg, particularly 10-50 mg per individual is suitable. The effective concentration reached at the cellular level can be set at about 0.05-200 μM, preferably about 0.01-100 μM, more preferably about 0.05-10 μM. Particularly preferred is topical administration, such as inhalation into the airway. In these cases, the dosage may conveniently be reduced to 0.1 to 10 mg per administration, preferably 0.2 to 5 mg per administration, which for a 70 kg subject is equivalent to about 3 to about 80 μg per kilogram.

[0071] Preferably, the method according to the invention is characterized in that the phosphorylation of TAD2 is located at Ser46 and / or Thr55 of human p53, or at a similar position of other mammalian p53 TADs, as further explained herein. Preferably, the phosphorylation of TAD2 is located at Thr55 of human p53, or at a similar position of other mammalian p53 TADs. In this aspect of the invention, it is further preferred that the method according to the invention further comprises detecting the amount of phosphorylation at Ser392 of human p53 or at a similar position of other mammalian p53 proteins, and comparing the amount with the amount in a sample previously obtained from the subject, and / or in a control sample, wherein an increase in phosphorylation also indicates the success and / or progress of anti-aging treatment or prevention in a mammalian subject.

[0072] Preferred is the method according to the present invention, wherein the biological sample obtained from the subject comprises senescent cells, tumor cells, metastatic cancer cells, micrometastatic and / or macrometastatic cells, and / or fibrotic cells, in particular breast cancer, ovarian cancer, pancreatic cancer, gastric cancer, pneumonia, and / or liver cancer cells or metastatic cells thereof.

[0073] Also preferred is a method according to the invention, wherein the subject is also receiving anti-senescent cell chemotherapy, such as anti-cancer chemotherapy.

[0074] Another aspect of the present invention relates to an anti-aging compound that improves specific binding to a TAD of a mammalian p53 protein, preferably TAD2, or a pharmaceutical composition comprising the anti-aging compound, preferably a compound or pharmaceutical composition for the prevention or treatment of senescent cells according to the present invention, for use in the prevention or treatment of senescent cells, wherein the senescent cells, when compared to control cells, exhibit an increase in the amount of phosphorylation of Ser46 and / or Thr55 of human p53, or a similar position of other mammalian p53 TADs, and / or an increase in the amount of PML protein. Preferably, the phosphorylation of TAD2 is located at Thr55 of human p53, or a similar position of other mammalian p53 TADs.

[0075] Also within this aspect of the invention, also preferred are improved anti-senescence compounds or pharmaceutical compositions for use according to the invention, wherein the senescent cells, when compared to control cells or control values, also exhibit an increase in the amount of phosphorylation at Ser392 of human p53 or a similar position of other mammalian p53 proteins.

[0076] Preferred is an improved anti-aging compound or pharmaceutical composition for use according to the present invention, wherein the biological sample obtained from the subject comprises senescent cells, tumor cells, metastatic cancer cells, micrometastatic cells, and / or fibrotic cells, in particular breast cancer, ovarian cancer, pancreatic cancer, gastric cancer, pneumonia, and / or liver cancer cells or metastatic cells thereof. As a result, preferred is an improved anti-aging compound or pharmaceutical composition for use according to the present invention, wherein the senescent cells are selected from tumor cells, metastatic tumor cells, tumor micrometastatic cells, fibrotic cells, breast cancer cells (e.g. triple-negative breast cancer cells), ovarian cancer, pancreatic cancer, gastric cancer, lung cancer, and / or liver cancer cells or metastatic cells thereof.

[0077] Also preferred are the improved anti-senescence compounds or pharmaceutical compositions for use according to the present invention, wherein the subject is also receiving anti-senescence cell chemotherapy, such as anti-cancer chemotherapy.

[0078] Another aspect of the present invention relates to a method for preventing or treating senescent cells in a subject, wherein the senescent cells, when compared to control cells, exhibit an increase in the amount of phosphorylation of Ser46 and / or Thr55 of human p53, or similar positions of other mammalian p53 TADs, and / or an increase in the amount of PML protein, comprising administering to the subject an effective amount of an anti-aging compound that specifically binds to the TAD of the p53 protein or a pharmaceutical composition comprising the anti-aging compound, preferably a compound or pharmaceutical composition according to the present invention. Preferably, the phosphorylation of TAD2 is located at Thr55 of human p53, or similar positions of other mammalian p53 TADs.

[0079] Also within this aspect of the invention, also preferred are methods according to the invention, wherein the senescent cells, when compared to control cells, also exhibit an increased amount of phosphorylation at Ser392 of human p53, or a similar position of other mammalian p53 proteins.

[0080] Preferred is the method according to the invention, wherein the senescent cells are selected from tumor cells, metastatic tumor cells, tumor micrometastasis cells, fibrotic cells, breast cancer cells (e.g. triple negative breast cancer cells), ovarian cancer, pancreatic cancer, gastric cancer, pneumonia, and / or liver cancer cells or metastatic cells thereof. As a result, preferred is the method according to the invention, wherein the senescent cells are selected from tumor cells, metastatic tumor cells, tumor micrometastasis cells, fibrotic cells, breast cancer cells (e.g. triple negative breast cancer cells), ovarian cancer, pancreatic cancer, gastric cancer, pneumonia, and / or liver cancer cells or metastatic cells thereof. Also preferred is the method according to the invention, wherein the subject also receives anti-senescent cell chemotherapy, e.g. anti-cancer chemotherapy.

[0081] In terms of the medical use of the present invention, (the use) compound can be provided and / or applied as a suitable pharmaceutical composition, such as tablets, capsules, injections, granules, powders, capsules, reconstituted powders, dry powder inhalers, inhalants, and / or chewables. Such solid dosage forms can include an appropriate amount of excipients and other ingredients. These solid dosage forms can include, for example, cellulose, microcrystalline cellulose, polyvinyl pyrrolidone (particularly FB polyvinyl pyrrolidone), magnesium stearate, etc. However, application can also be, for example, in the form of suppositories, per rectum, for example, in the form of injections or infusions, or, for example, in the form of ointments, creams or tinctures, percutaneously. Preferably, dry powder inhalers or other inhalation forms are used for application.

[0082] It will be understood that the present compound and / or pharmaceutical composition comprising the present compound is for administration to a human patient. The term "administering" refers to administering a single therapeutic agent or in combination with another therapeutic agent. Thus, it is contemplated that the pharmaceutical composition of the present invention is employed in a conjoint therapy, i.e., co-administered with other medicaments or drugs and / or any other therapeutic agent that may be beneficial in the context of the method of the present invention. However, other medicaments or drugs and / or any other therapeutic agent, if desired, may be administered separately from the compound used, as long as they act together (i.e., directly or indirectly, preferably synergistically) with the present compound of use.

[0083] Thus, the compounds of the present invention can be used alone or in combination with other active ingredients (e.g., with known agents for the treatment of the above-mentioned diseases), wherein in the latter case, advantageous additional, expanded, preferably synergistic effects are noted. Suitable amounts for administration to humans are 1-500 mg, particularly 5 mg-100 mg, such as 1-10 mg / kg / day oral doses. The effective concentration reached at the cellular level can be set at 0.005-200 μM, as noted above, preferably about 0.5-10 μM. Particularly preferred is topical administration, such as by inhalation to the airways. In these cases, the dosage can be conveniently reduced to 0.1-10 mg / each administration, preferably 0.2-5 mg per administration, which is equal to about 3-about 80 μg per kilogram for a 70 kg subject.

[0084] Another aspect of the invention relates to a diagnostic kit comprising, in one or separate containers, materials for practicing the method of the invention, optionally together with adjuvants and / or instructions for practicing the method.

[0085] Preferred is a diagnostic kit according to the present invention, which comprises an anti-aging candidate molecule, a TAD of a recombinantly expressed mammalian p53 protein, in particular comprising at least one of the N-terminal fragments of TAD1 or TAD2, preferably bound or coupled to a solid phase carrier.

[0086] The kit may also include FOXO4 or its TAD binding portion for practicing the above methods, relevant antibodies that bind to the components in the kit, radiolabeled 32P-orthophosphate, phosphorylation-specific and / or p53 conformation-specific antibodies (i.e., specific for the "open" form), dyes and other labels, as well as buffers and matrices.

[0087] The kits can be used in the methods of the invention, i.e., for identifying anti-aging compounds, for monitoring anti-aging treatment or prevention in a mammalian subject in need thereof, and / or for predicting or prognosing the success, progression and / or sensitivity of an anti-aging treatment or prevention in a mammalian subject.

[0088] The present invention relates to the following items.

[0089] Item 1. A method for identifying improved anti-aging compounds, comprising the following steps: a) contacting at least one anti-aging candidate molecule with a mammalian p53 protein transactivation domain (TAD), b) detecting specific binding of the candidate molecule to the TAD when at least one phosphorylated amino acid is present in the TAD, and c) comparing the specific binding with the binding when at least one phosphorylated amino acid is not present in the TAD, wherein an enhancement in binding when at least one phosphorylated amino acid is present in the TAD identifies an improved anti-aging compound.

[0090] Item 2. A method according to Item 1, wherein the contact is in vivo or in vitro, in solution or comprising a mammalian p53 protein TAD or an anti-aging candidate molecule bound to or coupled to a solid phase carrier.

[0091] Item 3. A method according to Item 1 or 2, wherein the anti-aging candidate molecule is selected from chemical molecules, molecules selected from an organic small molecule library, molecules from a selected combinatorial library, cell extracts, especially plant cell extracts, small molecule drugs, proteins, protein fragments, molecules selected from a peptide library, antibodies or fragments thereof, especially reverse-flip peptides obtained from mammalian FOXO4 protein, fusion peptides comprising reverse-flip peptides obtained from mammalian FOXO4 protein, and derivatives thereof, preferably peptides selected from CL04183, CL04124 and CL04177.

[0092] Item 4. A method according to any one of Items 1-3, wherein detection of the binding comprises detection of phosphorylation, comprising radiolabeled 32P orthophosphate, phosphorylation-specific antibodies, and / or mass spectrometry.

[0093] Item 5. A method according to any one of Items 1 to 4, wherein the TAD of the mammalian p53 protein is selected from TAD1 and / or TAD2 of human, mouse, rat, monkey, sheep, goat, hamster, dog and cat p53 proteins, optionally as part of the full-length p53 protein, in particular a recombinant p53 protein, a full-length p53 protein containing phosphorylation of human p53 Ser392 or similar positions of other mammalian p53 proteins, a recombinant fusion protein containing the TAD1 and / or TAD2, or a phosphorylated fragment of the TAD1 or TAD2, and mutants thereof.

[0094] Item 6. A method according to any one of Items 1 to 5, wherein the phosphorylation of the TAD1 domain is located at Ser15 and / or Ser20 of human p53, and / or the phosphorylation of the TAD2 is located at Ser46 and / or Thr55 of human p53, or at similar positions of other mammalian p53 TADs. Preferably, the phosphorylation of the TAD2 is located at Thr55 of human p53 or at similar positions of other mammalian p53 TADs.

[0095] Item 7. The method according to any one of Items 1-6, wherein the detection of the binding comprises competitive binding with protein FOXO4 or a TAD binding fragment thereof.

[0096] Item 8. A method according to any one of Items 1-7, wherein detecting the binding further comprises, when feasible, detecting phosphorylation at Ser392 of human p53 or similar positions of other mammalian p53 proteins, and comparing the specific binding with the absence of the phosphorylated amino acid.

[0097] Item 9. An anti-aging compound identified by the method according to any one of Items 1-8, or a pharmaceutical composition comprising the anti-aging compound and a pharmaceutically acceptable carrier.

[0098] Item 10. A method for monitoring anti-aging treatment or prevention in a mammalian subject in need thereof, comprising a) providing anti-aging treatment or prevention to the subject, comprising administering to the subject an anti-aging compound that specifically binds to the TAD of the p53 protein, or a pharmaceutical composition comprising the anti-aging compound, preferably a compound or pharmaceutical composition according to Item 9, b) detecting the amount of phosphorylation of amino acids in the TAD of the p53 protein in a biological sample obtained from the subject, and / or detecting the amount of promyelocytic leukemia protein (PML) bodies, and / or detecting the colocalization of promyelocytic leukemia protein (PML) bodies with phosphorylated p53 protein in its phosphorylated form in a biological sample obtained from the subject, and c) comparing the amount and / or colocalization detected in step b) with the amount and / or colocalization in a sample previously obtained from the subject and / or a control sample.

[0099] Item 11. A method for predicting or prognosing the success, progress and / or sensitivity of anti-aging treatment or prevention in a mammalian subject, comprising implementing a method according to Item 10, wherein an increase in the amount of phosphorylated and / or PML protein bodies and / or co-localization with phosphorylated p53 in its phosphorylated form indicates the success, progress and / or sensitivity of anti-aging treatment or prevention in the mammalian subject.

[0100] Item 12. The method according to Item 10 or 11, wherein the mammalian subject is a human, mouse, rat, monkey, sheep, goat, hamster, dog or cat.

[0101] Item 13. A method according to any one of Items 10-12, wherein the anti-aging treatment or prevention in the mammalian subject comprises administering an effective amount of a retro-flip peptide obtained from a mammalian FOXO4 protein, a fusion peptide comprising a retro-flip peptide obtained from a mammalian FOXO4 protein, and derivatives thereof, preferably a peptide selected from CL04183, CL04124 and CL04177 and their TAD2-binding derivatives or fragments thereof.

[0102] Item 14. The method according to any one of Items 10-13, wherein the phosphorylation of TAD2 is located at Ser46 and / or Thr55 of human p53, or a similar position of other mammalian p53 TADs. Preferably, the phosphorylation of TAD2 is located at Thr55 of human p53 or a similar position of other mammalian p53 TADs.

[0103] Item 15. The method according to any one of Items 10-14 also includes detecting the amount of phosphorylation at Ser392 of human p53, or a similar position of other mammalian p53 proteins, and comparing the amount with the amount in a sample and / or a control sample previously obtained from the subject, wherein an increase in phosphorylation also indicates the success and / or progress of anti-aging treatment or prevention in the mammalian subject.

[0104] Item 16. A method according to any one of Items 10-15, wherein the biological sample obtained from the subject contains senescent cells, tumor cells, metastatic cells, micrometastatic cells, and / or fibrotic cells, in particular breast cancer, ovarian cancer, pancreatic cancer, gastric cancer, lung cancer, and / or liver cancer cells or their metastatic cells.

[0105] Item 17. A method according to any one of Items 10-16, wherein the subject is also receiving anti-senescent cell chemotherapy, such as anti-cancer chemotherapy.

[0106] Item 18. Use of an anti-aging compound that specifically binds to the TAD of the p53 protein, or a pharmaceutical composition comprising the anti-aging compound, preferably a compound or pharmaceutical composition according to Item 9, in the prevention or treatment of senescent cells, wherein the senescent cells, compared to control cells, exhibit an increase in the amount of phosphorylation at Ser46 and / or Thr55 of human p53, or similar positions of other mammalian p53TAD, and / or an increase in the amount of PML protein bodies.

[0107] Item 19. Use of an anti-aging compound or pharmaceutical composition according to Item 18, wherein the senescent cells exhibit an increased amount of phosphorylation at Ser392 of human p53, or a similar position of other mammalian p53 proteins, compared to control cells.

[0108] Item 20. Use of an anti-aging compound or pharmaceutical composition according to Item 18 or 19, wherein the senescent cells are selected from tumor cells, metastatic tumor cells, tumor micrometastasis cells, fibrotic cells, breast cancer cells such as triple-negative breast cancer cells, ovarian cancer, pancreatic cancer, gastric cancer, lung cancer, and / or liver cancer cells or their metastatic cells.

[0109] Item 21. A method for preventing or treating senescent cells in a subject, wherein the senescent cells, when compared to control cells, exhibit an increase in the amount of phosphorylation at Ser46 and / or Thr55 of human p53, or similar positions in other mammalian p53 TADs, and / or an increase in the amount of PML protein, and / or an increase in the co-localization of phosphorylated p53 and PML, comprising administering to the subject an effective amount of an anti-aging compound that specifically binds to the p53 protein TAD or a pharmaceutical composition comprising the anti-aging compound, preferably a compound or pharmaceutical composition according to Item 9.

[0110] Item 22. A method according to Item 21, wherein the senescent cells, when compared to control cells, also exhibit an increased amount of phosphorylation at Ser392 of human p53 or a similar position of other mammalian p53 proteins.

[0111] Item 23. A method according to Item 21 or 22, wherein the senescent cells are selected from tumor cells, metastatic tumor cells, tumor micrometastasis cells, fibrotic cells, breast cancer cells such as triple-negative breast cancer cells, ovarian cancer, pancreatic cancer, gastric cancer, lung cancer, and / or liver cancer cells or their metastatic cells.

[0112] Item 24. A diagnostic kit comprising materials for carrying out the method according to any one of items 1-8 and 10-17, in one or separate containers, optionally together with adjuvants and / or instructions for carrying out the method.

[0113] Item 25. Use of the kit according to Item 24 in a method according to any of Items 1-8 and 10-17 for identifying anti-aging compounds, for monitoring anti-aging treatment or prevention in mammalian subjects in need thereof, and / or for predicting or prognosing the success, progression and / or sensitivity of anti-aging treatment or prevention in mammalian subjects. BRIEF DESCRIPTION OF THE DRAWINGS

[0114] The present invention will be further described in the following examples with reference to the accompanying drawings and sequence tables, but is not limited thereto. For the purpose of the present invention, all documents cited herein are fully incorporated herein by reference.

[0115] Figure 1 Shown is a schematic overview of the domain architecture of the human p53 protein, with a TAD at the N-terminus containing amino acids that can be phosphorylated (S15, S20, S46 and T55), and a C-terminal regulatory domain comprising amino acid S392 that can also be phosphorylated.

[0116] Figure 2 Results of fluorescence polarization binding assays showing the binding of recombinant FOXO4 forkhead box domains to p53 TAD1 or p53 TAD2 containing transcriptional activation domains TAD2 ) of p53 FITC-labeled peptide.

[0117] Figure 3 Results of binding assays are shown, showing that FOXO4 (A) and FOXO4-derived (e.g., mimetic) peptides (B) and (C) bind with significantly higher affinity to p53-TAD2 when phosphorylated at T55 or S46 (squares and triangles in A, upper two lines in B and C, respectively).

[0118] Figure 4It was shown that the FOXO4-derived peptide CL04183 can bind to full-length p53 in cells in the wild-type or T55 or S46 phosphorylation mimics, but not when these sites are unphosphorylated.

[0119] Figure 5 Immunohistochemistry images for PML bodies (labeled with PML and SP100), FOXO4, and phosphorylated p53 in individual cell nuclei are shown (DNA stained blue with Hoechst 33258). p53 phosphorylated at serine 46 or threonine 55 colocalizes with FOXO4 within / directly adjacent to PML bodies. Thus, PML bodies are representative of the pool of phosphorylated p53 and FOXO4 and can be used as a stain for technically difficult to detect phosphorylated-TP53 in tissues.

[0120] Figure 6 Shown is an immunohistochemistry picture of a biopsy from a human breast cancer, with nuclei in dark grey (DNA stained with Hoechst 33258) and PML in light grey, indicating high levels of nuclear PML bodies in the cancer cells themselves (approximately one third of patient biopsies in this population).

[0121] Figure 7 The relationship curve between the number of PML bodies and the sensitivity of FOXO4-derived peptide CL04177 in human breast cancer cell lines grouped by molecular subtypes is shown. Among the cell lines tested, all with high levels of PML bodies fell into the triple negative subtype (showing low levels of progesterone receptor, estrogen receptor and human epidermal growth factor receptor 2) and were highly sensitive to compound CL04177, while breast cancer cell lines that contained almost no PML bodies were less sensitive.

[0122] Figure 8 CL04183 and CL04177 were shown to specifically combat liver metastases, with CL04183 primarily eliminating micrometastases.

[0123] Fig. 9 CL04183 and 5-FU and their combination were shown to specifically combat liver metastases.

[0124] Fig.10A) Correlation of open P53 (Pab240 clone) and P53 pSer392 (EP155Y clone) staining in proliferating and senescent hTERT immortalized retinal pigment epithelial cell line RPE1 and human triple negative breast cancer cell line MDA-MB-231 is shown. Spearman rank correlation coefficient (0.93) is given; B) Correlation of open P53 (Pab240 clone) and P53 pSer392 (EP155Y clone) staining in a panel of 8 human breast cancer cell lines (including luminal, Her2 positive and triple negative). The Spearman rank correlation coefficient (0.88) is given; and C) Correlation between PML body counts / nuclear pixel (corrected for variations in nuclear size between cell lines) and nuclear P53 pSer392 staining intensity in 8 human breast cancer cell lines, and the effective dose (ED50, measured by MTS assay) that causes 50% population cell death after treatment of these cell lines with CL04177. Sensitive cell lines are highlighted with boxes.

[0125] Fig.11 It is shown that cancer cells that survive chemotherapy show increased PML bodies and phosphorylated p53. These cells are more sensitive to CL04183 treatment. A) Patient-derived colorectal cancer organoids CRC29 were treated with 5'-fluorouracil (5-FU) for 1 week. Afterwards, immunofluorescence staining was performed on the designated proteins. B) CRC29 organoids were treated with 5'-FU or irinotecan in 96-well plates. After 3 days, increasing concentrations of compound CL04183 were added to the cells, and cell viability was measured on the 8th day.

[0126] Fig.12 Shown in the context of WT and mutant p53, the co-localization dynamics of PML and phosphorylated p53 (S392). A) TP53 is overexpressed in the p53 loss-of-function cell line H1299 with its wild type (WT) or its most common mutant R175H. B) Quantitatively shown, p53 is stably expressed in its phosphorylated form (S392). In addition, PML is enriched in cells that overexpress mutant p53. C) The co-localization map shows 3 types of pools: co-localized white pixels of PML and p53 (S392), and PML aggregates are separated from p53 (S392), which are red and green, respectively. D) Most cells contain PML and S392, compared with cells containing one of them.

[0127] Fig.13The CL04177 peptide targets cells with increased PML bodies and phosphorylated p53. A) The triple-negative breast cancer cell line MDAMB231 was treated with the LD50 dose determined in the previous assay. Two days later, immunofluorescence staining was performed for the indicated proteins. B) Therapy survivors are primarily composed of cells containing low levels of these proteins. Figure 1 Thus, more robust and reliable antibodies against PML and p53(S392) act not only on representatives of open p53 and FOXO4, but also on PML and p53(S392)-representing sensitive cell pools.

[0128] Fig.14 The CL04177 peptide targets cells from multiple cancer types, with higher selectivity for cell lines that have been genetically engineered to express an "open" configuration of p53 due to TP53 mutations. Viability curves illustrate the response of two cell lines to the peptide, A) A2780 with wild-type p53 configuration, and B) p53 with an "open" configuration based on p53 gene mutations. C) Overview of ED50s for multiple types of cancer shows that cancers with an "open" p53 tendency based on gene mutations are more sensitive to the peptide CL04177.

[0129] Fig.15 It is shown that colon cancer cells express higher phosphorylated p53 than wild-type colon cells. A) Immunofluorescence staining of the indicated proteins on the patient-derived colorectal cancer organoid line CRC29 and wild-type (WT) colon organoids. B) WT and CRC organoids were treated with increasing concentrations of compounds CL04177 or CL04183. Cell viability was measured after 5 days.

[0130] Fig.16 It is shown that compounds identified according to the present invention, such as CL04183, bind more tightly to p53 phosphorylated at Ser46 / Thr55 than to unphosphorylated p53. A) An example of an isothermal titration calorimetry measurement using CL04183 and a recombinant form of the second transactivation domain of human p53 (TAD2). Based on this measurement, the binding affinity (Kd) was determined to be 5.5±1.3 μM. B) An overview of binding affinities measured similarly to A), extended to conditions where TAD2 is phosphorylated at Ser46, Thr55, or both. A strong affinity increase was noted when either was phosphorylated, and the effect increased when TAD2 was doubly phosphorylated. DETAILED DESCRIPTION

[0131] Example

[0132] Detection and curve fitting to generate LD50

[0133] To study the selectivity of different therapies for cancer cells, colorimetric cytotoxicity assays were performed two days after treatment. Cells from some different cancer types (breast, ovarian, pancreatic, gastric, lung and liver cancer) were cultured in 96-well plates with 4000 cells per well. They were treated with gradient dilutions of the compound (3 sets in parallel) and blank control treatment (FBS, because the peptides are dissolved in it). Cell viability was assessed using the AQeous One Solution Cell Proliferation Detection Kit according to the manufacturer's instructions. In short, the old culture medium was removed and 100 μl of fresh culture medium and 10 μl of CellTiter AqueousOne solution were added to each well. The plate was incubated at 37°C for 1 hour. The resulting colorimetric reaction was read at 490nm in a microplate absorbance microplate reader. Relative viability was determined by normalizing the results relative to the blank control (=100% survival). Drug-response curves (method of choice: inhibitor or agonist vs. response, respectively, with top defined as 100) were generated using GraphPad 9.2.0 software by nonlinear regression (curve fitting) with 4 parameters assuming the standard Hill equation. The lethal dose 50 (LD50) was determined as the concentration of drug that reduced viability by 50% in the MTS assay.

[0134] Immunohistochemical staining

[0135] Cell lines were grown on 12 mm diameter glass coverslips in 24-well plates. They were gently washed with phosphate buffered saline (PBS) and fixed with 4% paraformaldehyde (PFA) (v / v) in PBS at 4°C for 30 minutes. Afterwards, the cells were washed twice with Tris buffered saline (TBS) pH 7.0 and permeabilized with 0.1% Triton X-100 (v / v) in PBS for 2 minutes, followed by blocking with a solution of 2% w / v serum suitable for the secondary antibody (e.g., 2% horse serum and 2% goat serum) and 2% bovine serum albumin in TBS pH 7.0 (TBSB) at room temperature for 30 minutes. Afterwards, the coverslips were placed on a sealing film and incubated overnight at 4°C on a 50 μl drop of primary antibody diluted in TBSB. After washing three times with TBSB, the coverslips were incubated with secondary antibodies and 5 μg / ml Hoechst 33258 at room temperature in the dark for 1 hour. Afterwards, the coverslips were washed with distilled water and placed on glass slides.

[0136] In vivo anti-metastatic activity of FOXO4 modulating peptides in an orthotopic TNBC model (see Figure 8 )

[0137] Mice treated with PBS developed metastatic growth that was visualized by bioluminescence. Meanwhile, treatment of mice with the CL04183 and CL04177 peptides reduced the occurrence of visible metastases. Treatment of mice with both peptides reduced the incidence of liver metastases, as evidenced by bioluminescence of cancer cells in extracted livers.

[0138] Approval for this study was obtained through the local University Animal Experimentation Committee of the University Medical Center Utrecht (IVD-UMC; WP No. 9124-1-02 and -05). MDA-MB-231 cells containing firefly luciferase were orthotopically transplanted into NSG mice (NOD.Cg-Prkdc <scid>IL2rgmWij / Szj) (Cat. No. 005557) exposed inguinal mammary fat pad. After surgery, carprofen was injected sc as an analgesic. Animals were purchased from Charles River and maintained in a sterile environment.

[0139] In established tumors (>50 mm 3 ) mice to quantify tumor growth dynamics. Carrying volume 100-200mm 3 Mice with tumors were subcutaneously administered with peptides (2.5 mg / kg CL04183 and 10 mg / kg CL04177) or PBS daily for one week. After 2 weeks of recovery, the mice were sacrificed. For in vivo administration, the peptides were dissolved in PBS. Eleven mice per group were used and randomly assigned to different treatment groups before the start of the experiment.

[0140] To visualize tumor burden in live mice, mice were injected ip with luciferin substrate, 150 mg / kg, and imaged using a bioluminescence imager after 15 minutes of isoflurane anesthesia. Bioluminescence signals were analyzed using M3Vision software by using regions of interest (ROIs) around the primary tumor to assess BL signals around the tumor and around the upper abdomen and chest of the mouse to assess signals of cancer metastases. Signals were measured as photons / s / cm 2 .

[0141] CL04183 and 5'-fluorouracil reduce colorectal cancer metastasis to the liver (see Fig. 9 )

[0142] Colorectal cancer organoid line CRC29 was transplanted into the cecum of immunodeficient mice. Two weeks after transplantation, animals were treated with 5'-fluorouracil (5-FU) or PBS. After one week of chemotherapy treatment, mice were treated with 3 doses of CL04183 or PBS. A) Liver was stained for KU80 or human nucleoli to detect human cancer cells in mouse organs, and p-p53 (T55) or PML. B) The number of liver metastases per stained slide was counted by eye.

[0143] Experiments in mice were performed after approval by the Netherlands Animal Ethics Committee (WP No. 9124-1-03). NOD.Cg-Prkdcscid Il2rgtm1Wjl / SzJ / J mice were purchased from Charles River and kept in a sterile environment. The animals were anesthetized by ip injection of 75mg / kg ketamine and 0.5mg / kg dexmedetomidine, and sc injected with 5mg / kg carprofen as an analgesic. Afterwards, CRC29 organoids (250,000 cells) containing firefly luciferase constructs were transplanted into the cecum in 10μl collagen droplets. Two weeks after tumor cell transplantation, animals were treated with 50mg / kg 5'-fluorouracil (5-FU) or PBS. After one week of chemotherapy, mice were treated with 3 doses of 2.5mg / kg CL04183 or PBS. Four weeks after transplantation, mice were killed and tissues were collected for further manipulation.

[0144] Cell culture

[0145] Breast cancer cell lines (triple negative: BT549, BT20, Sum149T, MDA-MB-468, MDA-MB-231; Her2+: ZR7530, SKBR3, MDA-MB-361; luminal: MCF7, T47D), p53 loss-of-function lung cancer cell line H1299, and hTERT-immortalized retinal pigment epithelial cell line RPE1 were cultured in Dulbecco's modified Eagle's medium containing 4.5 g / mL glucose, 4 mM glutamine, 10% fetal bovine serum, 100 units of penicillin potassium / mL and 100 units of streptomycin sulfate / mL in a humidified incubator at 37°C, 5% CO2 and 5% oxygen.

[0146] Immunohistochemistry

[0147] Paraffin-embedded, formalin-fixed tissue sections were dehydrated in decreasing concentrations of xylene and ethanol before washing in pH 7.0 Tris-buffered saline (TBS) and boiling in 1 mM EDTA in TBS at pH 9.4 for 20 minutes to expose antigens. After the slides were cooled for 30 minutes, the tissues were permeabilized with 0.2% TX-100 in TBS at room temperature for 5 minutes. Afterwards, the sections were washed with TBS and incubated for 1 hour in a blocking buffer containing 2% w / v serum (e.g., donkey or goat) suitable for the secondary antibody and 0.1% fish gelatin in 1% BSA. The sections were then circled with a waterproof pen and incubated overnight at 4°C with primary antibodies diluted in TBS / 1% BSA. The next day, the tissues were washed 3 times with TBS before incubation for 1 hour with fluorescently labeled secondary antibodies (nuclear staining containing Hoechst 33258) diluted in blocking buffer. Afterwards, the slides were washed twice in TBS, incubated in Sudan Black solution for 20 min to reduce background, and washed in demineralized water. Afterwards, the sections were mounted with Vectashield and imaged using an LSM880 Zeiss confocal microscope.

[0148] Organoid culture

[0149] Organoids were grown in a humidified incubator at 37°C and 5% CO2. All organoids were cultured in Matrigel (Corning) droplets in Advanced DMEM / F12 (Lonza) supplemented with 1% glutamax, 1% penicillin / streptomycin, 1% (10 mM) HEPES, 10% Noggin conditioned medium, 2% B-27 (50X; (Thermo / Life Technologies), N-acetylcysteine ​​(Sigma-Aldrich, 1.25 mM)), A83-01 (Tocris, 500 nM) and SB203580 (Invitrogen / LifeTechnologies, 3 μM). For viability and apoptosis assays, organoids were passaged by resuspension in ice-cold medium and then centrifuged at 4°C in a 15 ml tube. The resulting pellet was trypsinized for 5 minutes at 37°C to obtain single cells, then washed twice with Advanced DMEM / F12 medium. The cells were resuspended in Matrigel and plated in 5 μl drops in 96-well plates. 15 minutes later 100 μl of fresh medium was added to the wells. Two days after plating, peptide and chemotherapy treatments were applied to the organoids.

[0150] MTS Testing

[0151] After six days of treatment, cells were incubated with 10 μl CellTiter Aqueous One Solution Cell Proliferation Assay (Promega) was incubated at 37°C for 1 hour for MTS assay, and then the absorbance was measured at 490 nm using Spectramax M5e.

[0152] Immunofluorescence organoids

[0153] CRC29 organoids were fixed in 4% w / v paraformaldehyde [PFA] at 4°C for 45 minutes and then washed with 1% w / v BSA in TBS. Organoids were then permeabilized with 0.1% TX-100 in TBS for 5 minutes at room temperature, washed again, and incubated in blocking buffer containing 2% w / v serum of the appropriate secondary antibody (e.g., donkey or goat) and 0.1% fish gelatin in 1% BSA for 1 hour at 4°C. After blocking, organoids were incubated with primary antibodies diluted in blocking buffer overnight at 4°C. The next day, organoids were washed twice at 4°C for 1 hour and then incubated with fluorescently labeled secondary antibodies diluted in blocking buffer overnight at 4°C. Organoids were then washed twice again at 4°C for 1 hour, and Hoechst 33342 was added to the second wash. Stained organoids were then cleared in glycerol-fructose and imaged using an LSM880 Zeiss confocal microscope.

[0154] Protein expression and purification

[0155] Expression constructs for the amino acid 86-207 (FOXO4 forkhead) fragment of human FOXO4 (Uniprot ID P98177) were generated by synthesizing the corresponding optimized FOXO4 cDNA constructs (Genscript) and inserting these cDNAs into the pETM11-His6-protein A-TEV cleavage site vector after NcoI / BamHI restriction digestion. For the expression of recombinant untagged His6-protein A tag-FOXO4 forkhead protein, the bacterial expression vector was transformed into E. coli BL21-DE3Star strain and 1 L expression culture was grown for 2 days in minimal medium supplemented with 6 g glucose and 3 g ammonium chloride (Sigma). Cells were diluted to OD (600 nm) 0.8 and induced with 0.5 mM IPTG, followed by 16 h protein expression at 20°C. Cell pellets were harvested and sonicated in a non-denaturing lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 20 mM imidazole, 2 mM tris (2-carboxyethyl) phosphine). Tagged recombinant proteins were purified using Ni-NTA agarose (QIAGEN) and treated with TEV protease to cleave the His6-protein A tag. Untagged proteins were then separated and secondary affinity purified using Ni-NTA beads. The final size exclusion chromatography purification step was performed in a gel filtration column (Superdex 75, GE Healthcare) in the target buffer. The protein concentration was estimated based on its absorbance at 280 nm, assuming that the ε at 280 nm was equal to the theoretical ε value.

[0156] Fluorescence anisotropy studies

[0157] Data were acquired in a ClarioStar plus microplate reader. Endpoint testing was performed with 200 flashes per well. Gain and focus were adjusted for each measurement using an excitation filter of 482 nm and an emission filter of 530 nm. Fluorescence intensity, parallel fluorescence polarization, and perpendicular fluorescence polarization were recorded. Data analysis was performed using MARS version 3.4 (BMG), Microsoft Excel, and GraphPadPrism version 8.

[0158] For the measurement, 116 μl of a solution of the specific Cleara peptide (1-100 μM) was prepared. Afterwards, 4 μl of FITC-labeled p53 peptide (stock concentration 15 μM, resulting in a final concentration of 500 nM) was added. Afterwards, 35 μl was transferred to each well of a 384-well plate. The measurement was performed in triplicate. If necessary, the setup was extended to lower concentrations to cover stronger interactions.

[0159] Anisotropy (r) is defined as the ratio of the polarization component to the total intensity (I T ) ratio: The excitation is polarized along the z-axis, and the emission of the fluorophore is symmetric around the z-axis, so I x =I y And I y =I || , get

[0160] The anisotropy values ​​obtained for each concentration of CL peptide can be used to determine the binding affinity using the following fitting function: Where R0 is the initial value, which depends on the measurement (to correct for compensation), B max is the maximum anisotropy, X corresponds to the CL peptide concentration, and K d Fitted to half maximum anisotropy.

[0161] Experiments using triple-negative breast cancer cell lines to study "opening" p53 (see Fig.10 )

[0162] Cell culture

[0163] Breast cancer cell lines (triple negative: BT549, BT20, Sum149T, MDA-MB-468, MDA-MB-231; Her2+: ZR7530, SKBR3, MDA-MB-361; luminal: MCF7, T47D), hTERT-immortalized retinal pigment epithelial cell line RPE1, and IMR90 normal fetal lung fibroblast cell line were cultured in Dulbecco's modified Eagle's medium containing 4.5 g / mL glucose, 4 mM glutamine, 10% fetal bovine serum, 100 units of penicillin potassium / mL and 100 units of streptomycin sulfate / mL in a humidified incubator at 37°C, 5% CO2 and 5% oxygen.

[0164] MTS Testing

[0165] After six days of treatment, cells were incubated with 10 μl CellTiter Aqueous One Solution Cell Proliferation Assay (Promega) was incubated at 37°C for 1 hour for MTS assay, and then the absorbance was measured at 490 nm using Spectramax M5e.

[0166] Immunohistochemistry

[0167] Breast cancer cell lines and RPE1 cell lines were grown on 12 mm diameter 1.5H glass coverslips in 24-well plates. They were gently washed with phosphate buffered saline (PBS) at room temperature and fixed with 4% paraformaldehyde (PFA) (v / v) in PBS at 4°C for 30 minutes. Afterwards, the cells were washed twice with tris buffered saline (TBS) and permeabilized with 0.1% Triton X-100 (v / v) in PBS for 2 minutes, followed by blocking with a solution of 2% w / v serum suitable for secondary antibodies (e.g., 2% horse serum and 2% goat serum) and 2% bovine serum albumin in TBS pH 7.0 (TBSB) at room temperature for 30 minutes. Afterwards, the coverslips were placed on a sealing film and incubated overnight at 4°C on a 50 μl drop of primary antibody diluted in TBSB. After washing three times with TBSB, the coverslips were incubated with secondary antibodies and 5 μg / ml Hoechst 33258 at room temperature in the dark for 1 hour. Afterwards, the coverslips were washed with distilled water and placed on glass slides.

[0168] Antibody

[0169] For p53 in the open configuration, cells were stained with 10 μg / mL of the pAb240 clone antibody against p53 (mouse monoclonal, supplied by Abcam of Cambridge UK, catalog number ab26; RRID: AB_303198) and 260 ng / ml of the clone EP155Y antibody against P53pSer392 (rabbit monoclonal, supplied by Abcam of Cambridge UK, catalog number ab33889; RRID: AB_776988).

[0170] Statistics

[0171] The association between p53 pSer392 and open p53 is given as the Spearman rank correlation coefficient calculated using the stats package in R (ver.4.1.1, (R Core Team (2018) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: https: / / www.r-project.org / )) and the p-value (two-sided alternative hypothesis) calculation is based on the AS 89 algorithm (Best, DJ and Roberts, DE (1975) 'Algorithm AS 89: The Upper Tail Probabilities of Spearman's Rho', Applied Statistics, 24(3), p.377. doi:10.2307 / 2347111).

[0172] The correlation between PML and phosphorylated p53 (S392) is given as the Spearman rank correlation coefficient, calculated by performing simple linear regression using GraphPad 9.2.0 software.

[0173] Exemplary (CL) peptides used

[0174] Preferred embodiments of peptides used or to be used according to the invention are:

[0175] CL04124: RKKASSKIEAAILDAFSQNWRFFKRPPRRRQRRKKRGAKIEAAILDAFSQNWRKRRRRQRRKKRG (SEQ ID NO: 1);

[0176] CL04177: RKKASSKIEAEILDAFSQNWRRKRPPRRRQRRKKRG (SEQ ID NO: 2); and

[0177] CL04183: AKIEAAILDAFSQNWRKRRRRQRRKKRG (SEQ ID NO: 3);

[0178] and a peptide comprising the following amino acid sequence:

[0179] KIEAEILDAFSQNWRKR (SEQ ID NO:4) (core sequence of CL04177 and CL04124); and

[0180] KIEAAILDAFSQNWRKR (SEQ ID NO: 5) (core peptide of CL04183);

[0181] The amino acids in the amino acid sequences herein are preferably D-amino acid residues.

[0182] Isothermal Titration Calorimetry (ITC)

[0183] Synthetic human p53 TAD2 (residues 37-57) and CL04183 were equilibrated in ITC buffer (20 mM Hepes, 50 mM NaCl, 0.04% NaN3, pH 7.0). ITC measurements were performed with a Malvern Microcal VP-ITC instrument at 25°C with 28 cycles of 10 μL injections. Integration of the peaks corresponding to each injection, subtraction of protein dilution effects, and correction for relative baselines were performed using Origin 7SR4 (Origin Scientific Corporations) analysis software provided by the manufacturer. Curve fitting was performed using the standard single-site model and gives the binding equilibrium constant (K) for complex formation. a ).< / scid>

Claims

1. A method for identifying improved anti-aging compounds comprising the following steps: a) contacting at least one anti-aging candidate molecule with the transactivation domain (TAD) of mammalian p53 protein, b) detecting specific binding of the candidate molecule to the TAD in the presence of at least one phosphorylated amino acid in the TAD, and c) comparing the specific binding to binding in the absence of the at least one phosphorylated amino acid in the TAD, Wherein the enhanced binding is present in the presence of the at least one phosphorylated amino acid in the TAD, an improved anti-aging compound is identified.

2. The method according to claim 1, wherein the contact is in vivo or in vitro, in solution or comprising the TAD of the mammalian p53 protein or the anti-aging candidate molecule bound or coupled to a solid phase carrier.

3. The method according to claim 1 or 2, wherein the anti-aging candidate molecule is selected from chemical molecules, molecules selected from organic small molecule libraries, molecules selected from combinatorial libraries, cell extracts, especially plant cell extracts, small molecule drugs, proteins, protein fragments, molecules selected from peptide libraries, antibodies or fragments thereof, especially retro-flipped peptides obtained from mammalian FOXO4 protein, fusion peptides comprising retro-flipped peptides obtained from mammalian FOXO4 protein, and derivatives thereof, preferably peptides selected from CL04183, CL04124 and CL04177 or their core sequences.

4. The method according to any one of claims 1-3, wherein detecting the binding comprises detecting phosphorylation, comprising radiolabeling 32P orthophosphate, phosphorylation-specific antibodies, and / or mass spectrometry.

5. The method according to any one of claims 1-4, wherein the TAD of the mammalian p53 protein is selected from TAD1 and / or TAD2 of human, mouse, rat, monkey, sheep, goat, hamster, dog and cat p53 proteins, optionally as part of the full-length p53 protein, in particular a recombinant p53 protein, a full-length p53 protein containing phosphorylation at Ser392 of human p53 or a similar position of other mammalian p53 proteins, a recombinant fusion protein comprising the TAD1 and / or TAD2, or a phosphorylated fragment of the TAD1 or TAD2, and mutants thereof.

6. The method according to any one of claims 1-5, wherein the phosphorylation of TAD1 is located at Ser15 and / or Ser20 of human p53, and / or the phosphorylation of TAD2 is located at Ser46 and / or Thr55 of human p53, or similar positions of other mammalian p53TADs.

7. The method according to any one of claims 1-6, wherein the detection of the binding further comprises, when feasible, detecting phosphorylation at Ser392 of human p53 or a similar position of other mammalian p53 proteins, and comparing the specific binding with that in the absence of the phosphorylated amino acid.

8. An anti-aging compound identified by the method of any one of claims 1-7, or a pharmaceutical composition comprising the anti-aging compound and a pharmaceutically acceptable carrier.

9. A method for monitoring anti-aging treatment or prevention in a mammalian subject in need thereof, wherein the mammal is preferably a human, comprising: a) providing anti-aging treatment or prevention to the subject, comprising administering to the subject an anti-aging compound that specifically binds to the TAD of the p53 protein, or a pharmaceutical composition comprising the anti-aging compound, preferably the compound or pharmaceutical composition according to claim 8, b) detecting the amount of phosphorylated amino acids in the TAD of the p53 protein in a biological sample obtained from the subject, and / or detecting the amount of promyelocytic leukemia protein (PML) bodies in a biological sample obtained from the subject, and / or detecting the co-localization of promyelocytic leukemia protein (PML) bodies and phosphorylated p53 protein in a biological sample obtained from the subject, and c) comparing the amount and / or co-localization detected in step b) with the amount and / or co-localization in a sample previously obtained from the subject and / or a control sample.

10. A method for predicting or prognosing the success, progression and / or sensitivity of an anti-aging treatment or prevention in a mammalian subject, wherein the mammal is preferably a human, comprising implementing the method of claim 9, wherein an increase in the amount of phosphorylated and / or PML proteosomes and / or co-localization of phosphorylated p53 with PML indicates the success, progression and / or sensitivity of an anti-aging treatment or prevention in the mammalian subject.

11. The method according to claim 9 or 10, wherein the anti-aging treatment or prevention in the mammalian subject comprises administering an effective amount of a retro-flip peptide obtained from a mammalian FOXO4 protein, a fusion protein comprising a retro-flip peptide obtained from a mammalian FOXO4 protein, and derivatives thereof, preferably a peptide selected from CL04183, CL04124 and CL04177 and their TAD2 binding derivatives or fragments such as core sequences.

12. The method according to any one of claims 9 to 11, wherein the phosphorylation of TAD2 is located at Ser46 and / or Thr55 of human p53, or similar positions of other mammalian p53 TADs.

13. The method according to any one of claims 9-12, further comprising detecting the amount of phosphorylation at Ser392 of human p53, or a similar position of other mammalian p53 proteins, and comparing the amount with the amount in a sample previously obtained from the subject and / or a control sample, wherein an increase in phosphorylation also indicates the success and / or progress of anti-aging treatment or prevention in the mammalian subject.

14. Use of an anti-aging compound that specifically binds to the TAD of the p53 protein, or a pharmaceutical composition comprising the anti-aging compound, preferably the compound or pharmaceutical composition according to claim 8, in preventing or treating senescent cells, wherein the senescent cells, compared with control cells, exhibit an increase in the amount of phosphorylation of Ser46 and / or Thr55 of human p53, or similar positions of other mammalian p53 TADs, and / or an increase in the amount of PML proteosomes, wherein preferably, the senescent cells, compared with control cells, also exhibit an increase in the amount of phosphorylation of Ser392 of human p53 or similar positions of other mammalian p53 proteins.

15. The use of an anti-aging compound or pharmaceutical composition according to claim 14, wherein the senescent cells are selected from tumor cells, metastatic tumor cells, tumor micrometastasis and / or macrometastasis cells, fibrotic cells, breast cancer cells such as triple-negative breast cancer cells, ovarian cancer, gastric cancer, pancreatic cancer, lung cancer, and / or liver cancer cells or their metastatic cells.